Details of Disease

General Information of Disease (ID: DISD09EG)

• Disease Name: Pleural tuberculosis
• Synonyms: pleura tuberculosis; tuberculosis of pleura; tuberculous pleurisy; tuberculous pleuritis; tuberculous pleurisy in primary progressive tuberculosis; pearly disease
• Definition: Inflammation of the pleura secondary to an infection with Mycobacterium tuberculosis.
• Disease Hierarchy:
  :
  DIS2YIMD: Tuberculosis
  DIS7OJYM: Respiratory tract infection
  DIS6KM28: Extrapulmonary tuberculosis
  DISD09EG: Pleural tuberculosis
• Disease Identifiers:
  MONDO ID: MONDO_0005922
  MESH ID: D014396
  UMLS CUI: C0041326
  MedGen ID: 22517
  SNOMED CT ID: 186182003

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cholecalciferol	DMGU74E	Approved	Small molecular drug	[1]
Ergocalciferol	DMHO0AR	Approved	Small molecular drug	[2]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 5 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ADA	TTLP57V	Strong	Altered Expression	[3]
CFP	TTLA0VS	Strong	Biomarker	[4]
IL17D	TTC5LTG	Strong	Biomarker	[5]
PEPD	TTLZXI0	Strong	Biomarker	[6]
RNF34	TTEWDK1	Strong	Biomarker	[7]

This Disease Is Related to 9 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
NCAPG2	OTZYENKO	Limited	Biomarker	[8]
BST1	OTAV5SE7	Strong	Biomarker	[9]
IL26	OT2WYCW4	Strong	Biomarker	[10]
IL27	OTIS3OF8	Strong	Biomarker	[5]
INTS4	OT5JQ913	Strong	Genetic Variation	[11]
MAX	OTKZ0YKM	Strong	Biomarker	[4]
RHOF	OTPA3F8Q	Strong	Biomarker	[7]
ROMO1	OTIEYVBW	Strong	Altered Expression	[12]
THEMIS	OTXODBXJ	Strong	Altered Expression	[13]

References

• [1] Cholecalciferol FDA Label
• [2] Ergocalciferol FDA Label
• [3] Impact of age on the diagnostic yield of four different biomarkers of tuberculous pleural effusion.Tuberculosis (Edinb). 2019 Jan;114:24-29. doi: 10.1016/j.tube.2018.11.004. Epub 2018 Nov 15.
• [4] The Performance of Pleural Fluid T-SPOT.TB Assay for Diagnosing Tuberculous Pleurisy in China: A Two-Center Prospective Cohort Study.Front Cell Infect Microbiol. 2019 Jan 30;9:10. doi: 10.3389/fcimb.2019.00010. eCollection 2019.
• [5] Biomarkers in the diagnosis of pleural diseases: a 2018 update.Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618808660. doi: 10.1177/1753466618808660.
• [6] Prolidase activity in serum and pleural fluids in patients with tuberculous pleural effusion [correction of effussion].Clin Biochem. 2008 Jun;41(9):670-5. doi: 10.1016/j.clinbiochem.2008.03.006. Epub 2008 Mar 20.
• [7] Xpert MTB/RIF Ultra improved the diagnosis of paucibacillary tuberculosis: A prospective cohort study.J Infect. 2019 Apr;78(4):311-316. doi: 10.1016/j.jinf.2019.02.010. Epub 2019 Feb 21.
• [8] Evaluation of Cepheid's Xpert MTB/Rif test on pleural fluid in the diagnosis of pleural tuberculosis in a high prevalence HIV/TB setting.PLoS One. 2014 Jul 22;9(7):e102702. doi: 10.1371/journal.pone.0102702. eCollection 2014.
• [9] CD157 Confers Host Resistance to Mycobacterium tuberculosis via TLR2-CD157-PKCzeta-Induced Reactive Oxygen Species Production.mBio. 2019 Aug 27;10(4):e01949-19. doi: 10.1128/mBio.01949-19.
• [10] Interleukin-26 upregulates interleukin-22 production by human CD4(+) T cells in tuberculous pleurisy.J Mol Med (Berl). 2019 May;97(5):619-631. doi: 10.1007/s00109-018-01741-1. Epub 2019 Mar 5.
• [11] NRAMP1 genetic polymorphisms as a risk factor of tuberculous pleurisy.Int J Tuberc Lung Dis. 2003 Apr;7(4):370-5.
• [12] Reactive oxygen species modulator 1 (Romo1) as a novel diagnostic marker for lung cancer-related malignant effusion.Medicine (Baltimore). 2017 Jan;96(4):e5975. doi: 10.1097/MD.0000000000005975.
• [13] Diagnosis of tuberculous pleurisy with combination of adenosine deaminase and interferon- immunospot assay in a tuberculosis-endemic population: A prospective cohort study.Medicine (Baltimore). 2017 Nov;96(47):e8412. doi: 10.1097/MD.0000000000008412.